Ramipril
- Generic Name
- Ramipril
- Brand Names
- Altace, Altace HCT
- Drug Type
- Small Molecule
- Chemical Formula
- C23H32N2O5
- CAS Number
- 87333-19-5
- Unique Ingredient Identifier
- L35JN3I7SJ
- Background
Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure...
- Indication
For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high ...
- Associated Conditions
- Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hearth Failure With Reduced Ejection Fraction (HFrEF), Hypertension, Myocardial Infarction, Nondiabetic proteinuric chronic kidney disease, Stroke, High risk cardiovascular event
- Associated Therapies
- -
Bariatric Surgery and Pharmacokinetics of Ramipril
- Conditions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Norwegian University of Science and Technology
- Target Recruit Count
- 12
- Registration Number
- NCT03440177
- Locations
- 🇳🇴
St. Olavs University Hospital, Trondheim, Norway
A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril
- Conditions
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT03414723
- Locations
- 🇩🇪
Investigational Site Number 2760001, Berlin, Germany
Renin-angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI)
- Conditions
- Interventions
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Hospital Clínico Universitario de Valladolid
- Target Recruit Count
- 194
- Registration Number
- NCT03201185
- Locations
- 🇪🇸
Hospital Clínico Universitario de Valladolid, Valladolid, Spain
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 5669
- Registration Number
- NCT02924727
- Locations
- 🇬🇧
Novartis Investigative Site, Worcester, United Kingdom
Doxazosin and Ramipril in Hypertension
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 71
- Registration Number
- NCT02901977
- Locations
- 🇸🇪
Karolinska Institutet, Daprtment of Clinical Sciences, Danderyd Hospital, Cardiovascular Research Laboratory, Stockholm, Sweden
Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis
- First Posted Date
- 2016-07-22
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 70
- Registration Number
- NCT02842424
- Locations
- 🇺🇸
VA Medical Center, Omaha, Nebraska, United States
Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension
- Conditions
- Interventions
- First Posted Date
- 2016-07-14
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Sao Jose do Rio Preto Medical School
- Target Recruit Count
- 72
- Registration Number
- NCT02832973
- Locations
- 🇧🇷
Juan Carlos Yugar-Toledo, São José do Rio Preto, São Paulo, Brazil
Perindopril vs Ramipril for Persistence in MAU Reduction Study
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2016-04-06
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 23
- Registration Number
- NCT02729441
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
- Conditions
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 31
- Registration Number
- NCT02632747
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial
- Conditions
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- Istituto Auxologico Italiano
- Target Recruit Count
- 168
- Registration Number
- NCT02499822
- Locations
- 🇨🇳
Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital Shanghai Institute of Hypertension, Shanghai Jiaotong University School of Medicine, Shanghai, China
🇬🇷Hypertension Center, Third University Department of Medicine, Sotiria Hospital, Athens, Greece
🇮🇹Istituto Auxologico Italiano, Milan, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.